Funding Opportunity RFA-CA-21-060 from the NIH Guide for Grants and Contracts. The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOAs (RFA-CA-21-061 or RFA-CA-21-062).

Funding Opportunity PAR-22-053 from the NIH Guide for Grants and Contracts. Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory function with clinical findings providing evidence of incompatibility between the symptoms and recognized neurological or medical conditions. FNDs are highly prevalent and associated with significant morbidity, health care costs, and even mortality. In some respects, this group of conditions sits at the intersection of neurology and psychiatry, but the majority of cases first come to the attention of neurologists. Management is complex and requires interdisciplinary approaches. Given the disability caused by the symptoms, and the high cost in healthcare utilization and loss of productivity, FNDs amount to a significant missed opportunity for therapeutic intervention and therefore, a healthcare crisis. Diagnosis and management of FNDs remain very challenging. Diagnostic criteria have been proposed but they are not universally agreed upon. Diagnosis is based on positive clinical findings, and can be supported by laboratory or ancillary investigation findings. Certain FND subtypes are more difficult to correctly diagnose than others. More importantly, laboratory-supported diagnosis is possible, and biomarkers can be developed, but significantly more research is needed in these areas to advance clinical management of FNDs. Therapies exist and have been studied in select populations but gathering high-level evidence through clinical trials is hampered by limitations in available outcome measures. Differential responses to treatments have been recorded, and thus, prediction of aggregate treatment response has been difficult. This FOA invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this FOA include the validation of biomarkers, endpoints and clinical outcome assessments (COA) that are fit-for-purpose and have a defined context of use for clinical trials.

Funding Opportunity RFA-AI-21-078 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center (RICC) for the global RePORT networks, whose mission is to advance regional and international TB and TB/HIV science, strengthen TB/HIV research capacity and infrastructure, and foster research collaboration. The RICC will coordinate the planning and implementation of research in TB and TB/HIV across all the RePORT networks and establish and maintain the required infrastructure to enable such research.

Notice NOT-CA-22-008 from the NIH Guide for Grants and Contracts

Experience with sequence data analysis using bioinformatics tools is strongly preferred. The Bioinformatician will be responsible for the processing, analysis,…
From PreventionGenetics LLC - Tue, 02 Nov 2021 01:29:40 GMT - View all Marshfield, WI jobs

Dependant on experience + competitive benefits: Singular Talent: Help shape the future of drug discovery, through data engineering, in one of the UK's fastest-growing biotechs. Oxford, Oxfordshire (GB)

Funding Opportunity PAR-22-054 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as epigenomic assays of tumor or affected tissue, when justified. These data, and associated clinical and phenotypic data, will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Expenses-paid trip. Opportunity to win cash prizes.: Merck KGaA: If you are a post-graduate student with an interest in the pharmaceutical industry, this is your chance to gain in-depth knowledge about... near Frankfurt, Germany

Expenses-paid trip. Opportunity to win cash prizes.: Merck KGaA: If you are a post-graduate student with an interest in the pharmaceutical industry, this is your chance to gain in-depth knowledge about... near Frankfurt, Germany

£37,000 - £45,000 per annum: General Bioinformatics: Combining scientific insight with bioinformatics analysis you will complete analyses to support genomics studies in non-model organisms. Reading, Berkshire (GB)

The qualified candidate should have received a doctoral degree in one of the relevant fields. Health insurance can be obtained through ORISE.
From Oak Ridge Associated Universities - Fri, 29 Oct 2021 20:12:34 GMT - View all Madison, WI jobs

Funding Opportunity RFA-HD-22-017 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to request applications to develop, adapt, and/or test physical activity interventions for individuals who use wheelchairs due to physical disability. The goal of the proposed interventions should be to safely prevent, or reverse chronic conditions associated with low physical activity such as diabetes, cardiovascular disease, and obesity. Inclusion criteria must be based on functional status rather than the primary condition leading to disability. Interventions that could be applied or easily adapted to large populations of wheelchair users and used in multiple settings are a priority.

Funding Opportunity RFA-AT-22-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life. In addition, studies that address stigma, structural health care system, and social factors that may hinder quality comprehensive pain care for patients with SCD are also of interest. Investigators are encouraged to include the collection of well-justified biological markers or psychological processes that have demonstrated that they may mediate pain outcomes. Trials should collect sufficient measures to phenotype participants such as type of pain, variability of pain, co-occurring conditions, and social determinants of health. The studies must address questions within the mission and research interests of the NIH HEAL Initiative and evaluate preventive or treatment strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, behavioral interventions, rehabilitation strategies, complementary interventions, integrated approaches, and delivery system strategies in well controlled trials in patients with SCD to manage acute and/or chronic pain.

Funding Opportunity RFA-AT-22-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials supported under this initiative could also address social and structural barriers such as stigma and racial bias to SCD pain management care. The overall goal of this initiative is to support the "real world" assessment of pain management interventions and/or health care strategies to enhance adherence to pain management guidelines in health care systems that may lead to improved SCD pain management, allowing access to opioid pain management when needed. This FOA requires that the intervention under study be embedded into health care delivery system, real world settings, and it is expected that most data will be obtained through the electronic records of the health care system. Trials should be conducted across three or more health care systems (HCS) that provide care to SCD patient populations. Clinical trials will be conducted within the infrastructure of the HEAL Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) Program Coordinating Center, which has dedicated pain, implementation science, and pragmatic clinical trial design. Awarded applicants will work with the Health Care Systems Research Collaboratory Coordinating Center (HCS CCC) (https://rethinkingclinicaltrials.org/) to facilitate further planning and refinement of the proposed study in partnerships with health care delivery systems.

Notice NOT-OD-22-008 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-005 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: The team at ELIXIR are growing and we are currently looking for a collaborative, self-starter to join us as an Outreach Officer - Industry.  You will Hinxton, Cambridgeshire, England

Funding Opportunity RFA-RM-22-004 from the NIH Guide for Grants and Contracts. Specifically, this FOA will be for novel and varied technology development projects to characterize rare cells at single cell level. As such, the review of the FOAs falls outside the mission and scope of any of the existing standing CSR study sections and will require additional expertise and review criteria.

Funding Opportunity RFA-RM-22-005 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration of promising tools, techniques and methods that can be integrated, scaled, and applied to multiple murine tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in murine tissues. The subsequent UH3 phase is to support initial validation in multiple optimization and scale-up, generation of production level data and the application of the technology to describe cellular senescence in a mouse life course situation (for example development or lifespan). Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.

Notice NOT-HS-22-004 from the NIH Guide for Grants and Contracts